title: Protective effect of C4a against hyperoxic lung injury via a macrophage-dependent but not a neutrophil/lymphocyte-dependent signaling pathway.
abstract: Complement anaphylatoxins have been investigated extensively; however, the role of complement anaphylatoxin C4a in hyperoxic lung injury has yet to be investigated. To the best of our knowledge, the present study is the first to demonstrate the role of C4a in hyperoxic lung injury in vitro and in vivo. BALB/c mice were ventilated with 100% oxygen with or without C4a treatment for 36 h. The body weight and the relative lung weight of the mice were determined, along with any morphological changes in the lung. The expression levels of interleukin (IL)-1, IL-6 and tumor necrosis factor-α (TNF-α) were quantified in the lung tissue and bronchoalveolar lavage fluid (BALF) samples by enzyme-linked immunosorbent assay (ELISA) and western blot analysis. The total cell count and the number of macrophages, neutrophils and lymphocytes in the BALF were determined using cytocentrifuge slides and a hemocytometer. Histamine release from total cells in the BALF was also analyzed. The relative mRNA expression levels of CD68, F4/80, CD64, CD19 and CD3 in the murine lung tissue were assessed by reverse transcription-quantitative polymerase chain reaction. The results revealed that hyperoxia induced lung injury and morphological changes, and increased the expression levels of IL-1, IL-6 and TNF-α, histamine release, the number of inflammatory cells, and the expression levels of CD68, F4/80, CD64, CD19 and CD3. The hyperoxia-induced morphological changes and inflammatory reaction were significantly attenuated in mice treated with C4a. Treatment with C4a also attenuated the increase in the total cell count, decreased the number of macrophages in the BALF, and suppressed the elevated mRNA expression levels of CD68 and F4/80 in the lung tissue samples. Conversely, treatment with C4a did not affect the number of neutrophils or lymphocytes in the BALF or the mRNA expression of CD64, CD19 and CD3 in lung tissue. In conclusion, C4a attenuated hyperoxic lung injury via a macrophage-dependent but not a neutrophil/lymphocyte-dependent pathway.
authors.affiliation: Department of Critical‑Care Medicine, Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Jiang
authors.affiliation: Department of Orthopedic Surgery, Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
authors.forename: Yubo
authors.initials: Y
authors.lastname: Ma
authors.affiliation: Department of Pediatric Medicine, Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
authors.forename: Jinfeng
authors.initials: J
authors.lastname: Yu
authors.affiliation: Department of Critical‑Care Medicine, Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
authors.forename: Haihong
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Critical‑Care Medicine, Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
authors.forename: Fengjie
authors.initials: F
authors.lastname: Xie
mesh_terms: D055371:Acute Lung Injury / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D001992:Bronchoalveolar Lavage Fluid; D015934:Complement C4a / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D018496:Hyperoxia / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D007249:Inflammation / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D007375:Interleukin-1 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D008070:Lipopolysaccharides; D008214:Lymphocytes / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D051379:Mice; D009504:Neutrophils / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D015703:Antigens, CD; D007375:Interleukin-1; D015850:Interleukin-6; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D015934:Complement C4a